Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Telomir Pharmaceuticals Inc TELO

Healthcare
Telomir Pharmaceuticals, Inc. is a United States-based company. The Company operates as pre-clinical-stage pharmaceutical company focused on developing TELOMIR-1 small molecule to lengthen the deoxyribonucleic acid’s (DNA) protective telomere caps to affect age reversal. It selectively affects the processes that drive the concentration and accumulation of iron and copper in the serum that... see more

Recent & Breaking News (NDAQ:TELO)

    Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

    Accesswire 1 day ago

    Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday

    Accesswire September 26, 2024

    Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

    Accesswire September 4, 2024

    Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs

    Accesswire August 20, 2024

    Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman

    GlobeNewswire August 12, 2024

    Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes

    GlobeNewswire July 2, 2024

    Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

    GlobeNewswire June 17, 2024

    Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

    GlobeNewswire May 30, 2024

    Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

    GlobeNewswire April 16, 2024

    Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

    GlobeNewswire April 2, 2024

    UPDATE - Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

    GlobeNewswire March 29, 2024

    Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

    GlobeNewswire March 26, 2024

    Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

    GlobeNewswire March 22, 2024

    Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal Science

    GlobeNewswire March 14, 2024

    Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference

    GlobeNewswire March 7, 2024

    Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal

    GlobeNewswire March 5, 2024

    Telomir Pharmaceuticals Announces Closing of Initial Public Offering

    GlobeNewswire February 13, 2024